Got to Love this Headline from 2/2020 ACTIPATCH
Post# of 7795
(Total Views: 408)
Posted On: 09/10/2020 3:55:37 PM
Got to Love this Headline from 2/2020
ACTIPATCH NOW CLEARED FOR “ALL” MUSCULOSKELETAL PAIN
In 2017, the FDA 510(k) cleared BioElectronics Corporation's ActiPatch, a drug-free therapy for over-the-counter (OTC) treatment of knee osteoarthritis (OA) and heel pain. On February 3, 2020, the company announced additional FDA clearance for “adjunctive treatment of musculoskeletal pain,” including pain in the back, knees, wrists, hips, elbows and ankles. In the company's words, the clearance expands these indications to cover "all musculoskeletal pain complaints."
It took the agency a little over five months to clear the additional indications.
Read the full article at 'Orthopedics This Week' , https://ryortho.com/breaking/actipatch-now-cl...etal-pain/
ACTIPATCH NOW CLEARED FOR “ALL” MUSCULOSKELETAL PAIN
In 2017, the FDA 510(k) cleared BioElectronics Corporation's ActiPatch, a drug-free therapy for over-the-counter (OTC) treatment of knee osteoarthritis (OA) and heel pain. On February 3, 2020, the company announced additional FDA clearance for “adjunctive treatment of musculoskeletal pain,” including pain in the back, knees, wrists, hips, elbows and ankles. In the company's words, the clearance expands these indications to cover "all musculoskeletal pain complaints."
It took the agency a little over five months to clear the additional indications.
Read the full article at 'Orthopedics This Week' , https://ryortho.com/breaking/actipatch-now-cl...etal-pain/
(1)
(0)BioElectronics Corporation (BIEL) Stock Research Links
Scroll down for more posts ▼